Acute Hip Fracture Study in Patients 65 Years or Greater
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to
investigate the safety, tolerability, and efficacy of VK5211 after 12 weeks of treatment.
Males and females ≥65 years old who are ambulatory and recovering from a hip fracture will be
eligible for participation 3-7 weeks post-injury.